文献速递淋巴瘤造血干细胞移植与细胞治疗

抗CD19嵌合抗原受体T细胞疗法治疗老年复发或难治性大B细胞淋巴瘤:一项多中心研究

Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study.
PubMed 文献 · Am J Hematol · 2024-06-04

这项多中心回顾性观察研究纳入7家美国机构226例≥65岁复发或难治性大B细胞淋巴瘤患者,评估抗CD19 CAR-T疗法的安全性与疗效。最佳客观缓解率和完全缓解率分别为86%和62%,中位无进展生存期6.9个月,180天非复发死亡率10.9%。年龄组不影响安全性、生存及非复发死亡结局。

要点

  • ≥65岁复发或难治性大B细胞淋巴瘤患者接受抗CD19 CAR-T,最佳客观缓解率86%、完全缓解率62%。
  • 中位无进展生存期6.9个月,6个月和12个月无进展生存估计分别为54%和44%。
  • 180天非复发死亡率10.9%,主要由感染导致,且不受年龄组影响。

核心结论

  • 这些发现支持在老年患者中使用CAR-T,包括≥80岁患者。
  • CAR-T治疗时的年龄不影响安全性、生存和非复发死亡结局。
  • 不应仅根据实际年龄将老年患者排除在CAR-T治疗之外。

研究设计与样本

  • 多中心、回顾性、观察性研究,纳入7家美国机构接受抗CD19 CAR-T治疗的≥65岁复发或难治性大B细胞淋巴瘤患者。
  • 共纳入226例患者,输注时中位年龄71岁(范围65-89)。
  • 输注后中位随访18.3个月。

主要发现

  • 最佳客观缓解率和完全缓解率分别为86%和62%。
  • 中位无进展生存期为6.9个月,6个月和12个月无进展生存估计分别为54%和44%。
  • 180天非复发死亡率为10.9%,主要由感染导致,且不受年龄组影响。
  • ≥3级细胞因子释放综合征和神经毒性分别发生于7%和26%。
  • 单因素分析中,无论年龄组或CAR-T类型,无进展生存均无显著差异;ECOG体能状态≥2、乳酸脱氢酶升高、大包块疾病、晚期分期、结外受累、需要桥接治疗以及既往苯达莫司汀暴露与更短的无进展生存相关。

临床怎么用

  • 作者认为这些发现支持在老年患者中使用CAR-T,包括≥80岁患者。
  • 作者认为不应仅根据实际年龄将老年患者排除在CAR-T治疗之外。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell (CAR-T) therapy, despite being a potentially curative therapy in relapsed or refractory (RR) large B-cell lymphoma (LBCL), remains underutilized in older patients due to limited clinical data. We therefore studied the safety and efficacy of CAR-T therapy in older patients with RR LBCL in the real-world setting. Patients aged ≥65 years with RR LBCL, treated with anti-CD19 CAR-T therapy at 7 US institutions were included in this multicenter, retrospective, observational study. In total, 226 patients were included. Median age at infusion was 71 years (range 65-89). Best objective and complete response rates were 86% and 62%, respectively. Median follow-up after infusion was 18.3 months. The median progression-free survival (PFS) was 6.9 months, with 6- and 12-month PFS estimates of 54% and 44%, respectively. The nonrelapse mortality (NRM) rate was 10.9% at day 180, primarily due to infections, and not impacted by the age groups. Grade ≥3 cytokine release syndrome and neurotoxicity occurred in 7% and 26%, respectively. In univariate analysis, no significant difference in PFS was seen regardless of the age groups or CAR-T type, whereas ECOG PS ≥2, elevated LDH, bulky disease, advanced stage, extranodal involvement, the need for bridging therapy, and prior bendamustine exposure were associated with shorter PFS. These findings support the use of CAR-T in older patients, including those aged ≥80 years. The age at CAR-T therapy did not influence safety, survival, and NRM outcomes. Older patients should not be excluded from receiving CAR-T therapy solely based on their chronological age.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tun AM, Patel RD, St-Pierre F, et al. Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study. Am J Hematol. 2024. PMID: 38837403. doi:10.1002/ajh.27381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。